|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 3/05/24 Bionano Genomics, Inc. 10-K 12/31/23 105:13M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.60M
2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 31K
3: EX-4.5 Instrument Defining the Rights of Security Holders HTML 42K
4: EX-22.1 Published Report re: Matters Submitted to a Vote HTML 29K
of Security Holders
5: EX-23.1 Consent of Expert or Counsel HTML 28K
10: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 51K
Awarded Compensation
6: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 33K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 31K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 31K
16: R1 Cover HTML 96K
17: R2 Audit Information HTML 34K
18: R3 Consolidated Balance Sheets HTML 150K
19: R4 Consolidated Balance Sheets (Parenthetical) HTML 49K
20: R5 Consolidated Statements of Operations HTML 110K
21: R6 Consolidated Statements of Comprehensive Loss HTML 55K
22: R7 Consolidated Statements of Stockholders? Equity HTML 95K
(Deficit)
23: R8 Consolidated Statements of Cash Flows HTML 177K
24: R9 Organization and Operations HTML 37K
25: R10 Summary of Significant Accounting Policies HTML 127K
26: R11 Revenue from Contracts with Customers HTML 55K
27: R12 Investments and Fair Value Measurements HTML 214K
28: R13 Prepaid Expenses and Other Current Assets HTML 41K
29: R14 Property and Equipment, Net HTML 41K
30: R15 Intangible Assets, Net HTML 55K
31: R16 Accrued Expenses HTML 41K
32: R17 High Trail Agreement HTML 64K
33: R18 Stockholders? Equity and Stock-Based Compensation HTML 112K
34: R19 Commitments and Contingencies HTML 81K
35: R20 Income Taxes HTML 97K
36: R21 Employee Benefits HTML 31K
37: R22 Acquisitions HTML 58K
38: R23 Related Party Transactions HTML 34K
39: R24 Pay vs Performance Disclosure HTML 41K
40: R25 Insider Trading Arrangements HTML 35K
41: R26 Summary of Significant Accounting Policies HTML 161K
(Policies)
42: R27 Summary of Significant Accounting Policies HTML 78K
(Tables)
43: R28 Revenue from Contracts with Customers (Tables) HTML 52K
44: R29 Investments and Fair Value Measurements (Tables) HTML 210K
45: R30 Prepaid Expenses and Other Current Assets (Tables) HTML 42K
46: R31 Property and Equipment, Net (Tables) HTML 40K
47: R32 Intangible Assets, Net (Tables) HTML 56K
48: R33 Accrued Expenses (Tables) HTML 41K
49: R34 High Trail Agreement (Tables) HTML 40K
50: R35 Stockholders? Equity and Stock-Based Compensation HTML 96K
(Tables)
51: R36 Commitments and Contingencies (Tables) HTML 88K
52: R37 Income Taxes (Tables) HTML 96K
53: R38 Acquisitions (Tables) HTML 59K
54: R39 Organization and Operations (Details) HTML 72K
55: R40 Summary of Significant Accounting Policies - HTML 101K
Additional Information (Details)
56: R41 Summary of Significant Accounting Policies - HTML 36K
Accounts Receivable (Details)
57: R42 Summary of Significant Accounting Policies - HTML 36K
Changes of Allowance for Credit Losses (Details)
58: R43 Summary of Significant Accounting Policies - HTML 42K
Inventories (Details)
59: R44 Summary of Significant Accounting Policies - HTML 41K
Goodwill (Details)
60: R45 Summary of Significant Accounting Policies - HTML 44K
Potentially Dilutive Securities not Included in
Calculation of Diluted Net Loss Per Share
Attributable to Common Stockholders (Details)
61: R46 Revenue from Contracts with Customers (Details) HTML 67K
62: R47 Investments and Fair Value Measurements - HTML 104K
Financial Assets and Liabilities (Details)
63: R48 Investments and Fair Value Measurements - HTML 91K
Additional Information (Details)
64: R49 Investments and Fair Value Measurements - HTML 63K
Estimated Fair Value Assumption (Details)
65: R50 Investments and Fair Value Measurements - Level 3 HTML 58K
Measurement (Details)
66: R51 Investments and Fair Value Measurements - HTML 85K
Amortized Cost and Unrealized Gains (Losses)
(Details)
67: R52 Investments and Fair Value Measurements - HTML 71K
Unrealized Losses Positions (Details)
68: R53 Prepaid Expenses and Other Current Assets HTML 48K
(Details)
69: R54 Property and Equipment, Net - Property and HTML 46K
Equipment, net (Details)
70: R55 Property and Equipment, Net - Additional HTML 33K
Information (Details)
71: R56 Intangible Assets, Net - Intangible Assets HTML 44K
(Details)
72: R57 Intangible Assets, Net - Additional Information HTML 47K
(Details)
73: R58 Intangible Assets, Net - Future Amortization of HTML 44K
Intangible Assets (Details)
74: R59 Accrued Expenses (Details) HTML 48K
75: R60 High Trail Agreement - Additional Information HTML 163K
(Details)
76: R61 High Trail Agreement - Schedule of Convertible HTML 43K
Debt (Details)
77: R62 High Trail Agreement - Schedule of Future HTML 44K
Aggregate Redemption (Details)
78: R63 Stockholders? Equity and Stock-Based Compensation HTML 228K
- Additional Information (Details)
79: R64 Stockholders? Equity and Stock-Based Compensation HTML 57K
- Warrant Activity (Details)
80: R65 Stockholders? Equity and Stock-Based Compensation HTML 73K
- Stock Option Activity (Details)
81: R66 Stockholders? Equity and Stock-Based Compensation HTML 60K
- Restricted Stock and Performance Stock Activity
(Details)
82: R67 Stockholders? Equity and Stock-Based Compensation HTML 49K
- Recognized Stock-Based Compensation Expense
(Details)
83: R68 Stockholders? Equity and Stock-Based Compensation HTML 38K
- Assumptions (Details)
84: R69 Commitments and Contingencies - Additional HTML 80K
Information (Details)
85: R70 Commitments and Contingencies - Supplemental HTML 52K
Information (Details)
86: R71 Commitments and Contingencies - Lease Cost HTML 48K
(Details)
87: R72 Commitments and Contingencies - Undiscounted HTML 77K
Future Non-Cancellable Lease Payments Under Leases
(Details)
88: R73 Income Taxes - Domestic and Foreign Components of HTML 38K
Income (Loss) (Details)
89: R74 Income Taxes - Provision for Domestic and Foreign HTML 56K
Income Taxes (Details)
90: R75 Income Taxes - Effective Income Tax Rate HTML 56K
Reconciliation (Details)
91: R76 Income Taxes - Deferred Tax Assets (Details) HTML 54K
92: R77 Income Taxes - Additional Information (Details) HTML 71K
93: R78 Income Taxes - Unrecognized Tax Benefits (Details) HTML 38K
94: R79 Employee Benefits (Details) HTML 30K
95: R80 Acquisitions - Additional Information (Details) HTML 47K
96: R81 Acquisitions - Acquisition Purchase Price HTML 39K
(Details)
97: R82 Acquisitions - Fair Value of Tangible and HTML 64K
Identifiable Assets Acquired and Liabilities
Assumed (Details)
98: R83 Acquisitions - Identifiable Intangible Assets HTML 39K
(Details)
99: R84 Acquisitions - Pro Forma Information (Details) HTML 38K
100: R85 Related Party Transactions (Details) HTML 34K
102: XML IDEA XML File -- Filing Summary XML 188K
105: XML XBRL Instance -- bngo-20231231_htm XML 2.55M
101: EXCEL IDEA Workbook of Financial Report Info XLSX 162K
12: EX-101.CAL XBRL Calculations -- bngo-20231231_cal XML 346K
13: EX-101.DEF XBRL Definitions -- bngo-20231231_def XML 979K
14: EX-101.LAB XBRL Labels -- bngo-20231231_lab XML 2.50M
15: EX-101.PRE XBRL Presentations -- bngo-20231231_pre XML 1.65M
11: EX-101.SCH XBRL Schema -- bngo-20231231 XSD 244K
103: JSON XBRL Instance as JSON Data -- MetaLinks 710± 1.01M
104: ZIP XBRL Zipped Folder -- 0001411690-24-000013-xbrl Zip 750K
 | Download this zipped .zip folder |
| Files: | bngo-20231231.htm bngo-20231231.xsd bngo-20231231_cal.xml bngo-20231231_def.xml bngo-20231231_g1.jpg bngo-20231231_g2.jpg bngo-20231231_g3.jpg bngo-20231231_g4.jpg bngo-20231231_g5.jpg bngo-20231231_g6.jpg bngo-20231231_g7.jpg bngo-20231231_lab.xml bngo-20231231_pre.xml bngo-ex221x20231231.htm bngo-ex311x20231231.htm bngo-ex312x20231231.htm bngo-ex321x20231231.htm bngo-ex322x20231231.htm bngo-ex41x20231231.htm bngo-ex45x20231231.htm bngo-ex971x20231231.htm exhibit231-bdoauditorconse.htm |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/08/24 Bionano Genomics, Inc. 10-Q 3/31/24 69:8.3M 5/08/24 Bionano Genomics, Inc. S-8 5/08/24 4:100K Broadridge Fin’l So… Inc 4/08/24 Bionano Genomics, Inc. 424B5 1:711K Broadridge Fin’l So… Inc |